David Lewis

David Lewis has extensive work experience in the biotechnology and pharmaceutical industries. David most recently served as the Head of Therapeutic Development at Empirico Inc. since November 2018. Prior to that, they were the President of Rudder Grange BioConsulting, LLC from December 2016 to October 2018, where they specialized in drug discovery and translation to clinical development.

From 2011 to 2016, David held various roles at Arrowhead Pharmaceuticals, including Chief Scientific Officer and Vice President and Site Head. David also worked at Roche as Vice President and Site Head from 2011 to 2011, and as Program Director - RNAi from 2008 to 2011.

David's earlier experience includes being a Program Director - RNAi at Mirus Bio Corporation from 2004 to 2008, a Senior Scientist at Mirus Corporation from 2000 to 2004, and a Post-Doctoral Research Associate at Howard Hughes Medical Institute - University of Wisconsin from 1996 to 2000.

Throughout their career, David has demonstrated expertise in RNA-based therapeutics, disease models, safety assessment, DMPK/ADME, and regulatory filings.

David Lewis earned a Bachelor of Science (BS) degree in Biochemistry/Molecular Biology from the University of Wisconsin-Madison, where they studied from 1981 to 1985. David then pursued further education at Michigan State University, where they obtained their PhD and completed their Post-Doctoral studies in the field of Biochemistry, spanning from 1987 to 1995. Following this, they continued their Post-Doctoral studies in Developmental Biology at the University of Wisconsin-Madison from 1995 to 2000.